HSK-36357

Phase I (Part A): Single-dose phase (SAD) Main objective: To evaluate the safety and tolerability of single-dose HSK36357 capsules in healthy subjects; Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of HSK36357 capsules after single-dose in healthy subjects; 2. To evaluate the effect of food on the pharmacokinetics of HSK36357 capsules after single-dose; Exploratory objectives: 1. To preliminarily explore the identification and main excretion pathways of HSK36357 metabolites in humans, and to investigate the cumulative excretion rates of HSK36357 parent drug and metabolites (if applicable) in urine and feces. 2. To preliminarily evaluate the effect of HSK36357 capsules on the QT interval. Phase II (Part B): Multiple-dose phase (MAD) Main objective: To evaluate the safety and tolerability of multiple-dose HSK36357 capsules in healthy subjects; Secondary objectives: To evaluate the pharmacokinetic characteristics of HSK36357 capsules after multiple-dose in healthy subjects.